Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2005
At a glance
- Drugs Irinotecan (Primary)
- Indications Leukaemia; Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- 27 Sep 2005 New trial record.